Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor‐positive/human epidermal growth factor receptor 2‐negative metastatic breast cancer

Palbociclib is a cyclin‐dependent kinase 4/6 inhibitor indicated for treatment of hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer in combination with endocrine therapy. We investigated the efficacy and safety of palbociclib in patients enrolled in N...

Descripción completa

Detalles Bibliográficos
Autores principales: Gelmon, Karen A., Cristofanilli, Massimo, Rugo, Hope S., DeMichele, Angela M., Joy, Anil A., Castrellon, Aurelio, Sleckman, Bethany, Mori, Ave, Theall, Kathy Puyana, Lu, Dongrui R., Huang, Xin, Bananis, Eustratios, Finn, Richard S., Slamon, Dennis J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7155112/
https://www.ncbi.nlm.nih.gov/pubmed/31448513
http://dx.doi.org/10.1111/tbj.13516

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7155112/
https://www.ncbi.nlm.nih.gov/pubmed/31448513
http://dx.doi.org/10.1111/tbj.13516

Ejemplares similares